Associated tags: P.C, News, Telephone, Defendant, Complaint
Locations: NEW JERSEY, PENNSYLVANIA, GEORGIA, FLORIDA, VIRGINIA, BRAZIL, INDIA, MARYLAND, LORDSTOWN, ALABAMA, OKLAHOMA, ILLINOIS, UK, COLORADO, LOS ANGELES, AMERICAS, ISRAEL, ASIA PACIFIC, OLO, CONNECTICUT, CAYMAN ISLANDS, TWIST, ARDS, AUSTRALIA, ALICO, NEW MEXICO, NEW SOUTH WALES, PUERTO RICO, NORFOLK, MOBILE, APACHE, SEAGATE, IDAHO, LASSO, SOUTH AMERICA, COLOMBIA, DISTRICT OF COLUMBIA, DANAHER, EASTERN, KEY, HAWAII, STANLEY, BOSTON, ARGENTINA, WILEY, HAIR, FIDELIS, III, STEINER, EUA, BLACKSTONE, BLUE RIDGE, CUMMINS, SIEMENS, NEW YORK, NY, US, UNITED STATES, TEXAS, APODACA, MEXICO, MONTERREY, NORTH AMERICA, MARKAZI, SPAC, TD, ROYALTON, LUNA, AD, CALIFORNIA, DELAWARE, SAN FRANCISCO, NEVADA, MASSACHUSETTS, NUEVO, MA, CENTRAL DISTRICT, EUROPEAN UNION, EUROPE, ARIZONA, OPPENHEIMER, TENNESSEE, CAMBODIA, CHINA, FAA, AFRICA, LATIN AMERICA, IL, MIDDLE EAST, JAPAN, ASIA
Radiation,
CKPT,
Biologics license application,
Telephone,
District court,
Patient,
CRL,
News,
Acquisition,
Complaint,
P.C,
CMO,
FDA,
BLA,
Court,
Food,
Person,
Pharmaceutical industry Investors have until June 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Key Points:
- Investors have until June 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- Checkpoint's lead antibody product candidate is cosibelimab for the treatment of selected recurrent or metastatic cancers.
- The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
- cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party [CMO] as approvability issues to address in a resubmission."
Psoriasis,
Form,
Patient,
Defendant,
News,
IPO,
Crohn's disease,
Security (finance),
Inflammation,
Rett syndrome,
Prospectus,
Complaint,
P.C,
Clinical trial,
MCI,
Radar,
File,
Register,
Pharmaceutical industry The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Key Points:
- The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
- In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
- On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
- For more information on the Anavex class action go to: https://bespc.com/cases/AVXL
Annual report,
Ethics,
CFO,
Weapon,
Risk,
School,
Air conditioning,
Electronics,
Snowflake Inc.,
News,
Controller,
Refrigeration,
Form 10-K,
IPO,
Transport,
Senior,
SNOW,
Complaint,
Adjustment,
P.C,
Plastic,
Audit committee,
Cryptocurrency Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
Key Points:
- Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
- which lowered credit consumption.” On this news, the price of Snowflake Class A common stock fell nearly 28% over several trading sessions, damaging investors.
- After the market closed on February 9, 2023, Chemours announced its fourth quarter and full year 2022 financial results.
- For more information on the Evolv class action go to: https://bespc.com/cases/EVLV
Research,
Class Action,
Growth,
Palo Alto Networks,
Federation,
Defendant,
Food and Drug Administration,
Dermatology,
News,
AI,
Nature,
Silicon,
Complaint,
P.C,
Goldengate,
Research and development,
Fox Factory,
Confidentiality,
Injury,
Wolfpack,
Marketing,
Dentist,
FDA InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.
Key Points:
- InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.
- Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
- The complaint further alleges that when these misleading statements and omissions about Fox Factory’s business reached the market, investors were harmed significantly.
- For more information on the Palo Alto Networks class action go to: https://bespc.com/cases/PANW
Signature,
Telephone,
District court,
ACL,
Defendant,
News,
NYCB,
Complaint,
P.C,
Assumption,
Category,
Court,
Person Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Key Points:
- Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.
- NYCB is engaged in several national businesses, including multi-family lending, mortgage originations and servicing, and warehouse lending.
- On January 31, 2024, before the market opened, NYCB announced its fiscal fourth quarter 2023 financial results.
Transport,
UAL,
Tax,
Telephone,
Aviation,
Bloomberg,
Total revenue,
P.C,
Safety,
Federal Aviation Administration,
Airline NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against United Airlines Holdings, Inc. (“United” or the “Company”) (NASDAQ: UAL) on behalf of United stockholders.
Key Points:
- NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against United Airlines Holdings, Inc. (“United” or the “Company”) (NASDAQ: UAL) on behalf of United stockholders.
- Our investigation concerns whether United has violated the federal securities laws and/or engaged in other unlawful business practices.
- Chicago, IL based United Airlines Holdings, Inc., through its subsidiaries, provides air transportation services in North America, Asia, Europe, Africa, the Pacific, the Middle East, and Latin America.
- Shares of United Airlines Holdings, Inc. (NASDAQ: UAL) reached as high as $58.23 per share in July 2023.
Sickle cell disease,
Biotechnology,
Luna Innovations,
Bluebird,
Blue,
DSM-IV codes,
Patient,
Defendant,
History,
News,
Cancer,
Bank statement,
False,
Complaint,
P.C,
Elivaldogene autotemcel,
File,
SCD,
FDA,
BLA,
Food Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
Key Points:
- Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
- Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
- According to the complaint, the Company’s announcement provided investors with false and misleading information in order to bolster investor expectations and share prices.
- For more information on the Luna Innovations class action go to: https://bespc.com/cases/LUNA
NBH,
Health,
Patient,
Metamaterial,
Meta,
Copper,
Truist,
Class,
News,
Disclosure,
Complaint,
P.C,
Medicare,
Barclays,
Cryptocurrency In return, agilon takes on the responsibility of managing the total cost and quality of care for those patients.
Key Points:
- In return, agilon takes on the responsibility of managing the total cost and quality of care for those patients.
- This model incentivizes agilon and its contracted physician partners to focus on preventive care and improve health outcomes in order to control costs.
- If the total cost of caring for patients is less than the fixed payments agilon receives, it realizes a profit.
- Securities analysts were shocked by the disclosure and linked Shoals’ sharp stock price decline to the warranty charge.
SSS,
Vii,
Telephone,
District court,
AUV,
Bloomberg Businessweek,
Sale,
News,
P.C,
Geisler,
Court,
Person Investors have until April 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Key Points:
- Investors have until April 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- Click here to participate in the action.
- On this news, the price of Xponential common stock fell more than 37%.
- There is no cost or obligation to you.
Cassava Sciences,
Science,
Initiative,
Alzheimer's disease,
Telephone,
Patient,
Defendant,
City University,
Journal,
Biomarker,
News,
Scientific misconduct,
Complaint,
P.C,
Neurobiology of Aging,
Cognition,
Safety,
Data management,
FDA,
Pharmaceutical industry Our investigation concerns whether the board of directors of Cassava have breached their fiduciary duties to the company.
Key Points:
- Our investigation concerns whether the board of directors of Cassava have breached their fiduciary duties to the company.
- The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
- However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
- On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
